25
Oct
2010
25
Oct
2010
Posted in I - Series D, Q - 3Q10, R - NORTH EAST, X - Inflammation, X - Pain, XX - CT
Cara Therapeutics (Shelton, CT) a clinical-stage small molecule company focused on pain and inflammation, closed a $15M Series D financing. Participants include Rho Ventures, Alta Partners, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Mitsubishi International and MVM Life Science Partners.
25
Oct
2010
25
Oct
2010
Posted in I - Series D, Q - 3Q10, R - MID WEST, X - Device (Spine), XX - OH
And cue the confetti cannon as we celebrate the 1,000th OnBioVC.com post!
AxioMed Spine (Cleveland, OH) a clinical-stage medical device company focused on lumbar disc replacement, closed a $15M Series D financing. Participants have included Thomas, McNerney & Partners, CID Equity Partners, Early Stage Partners, Investor Growth Capital, MB Venture Partners, Primus Capital Funds and Reservoir [...]
25
Oct
2010
25
Oct
2010
Posted in I - Series B, Q - 3Q10, R - MID WEST, X - Device (Cardiology), XX - MN
SuperDimesnion (Minneapolis, MN) a commercial-stage medical device company focused on minimally invasive distal lung disease treatments, closed a $9.8M Series B financing. Participants include Dan Sullivan Investments, Medica Venture Partners, OrbiMed, Oxford Biosciences Partners and Pitango Venture Capital.
25
Oct
2010
22
Oct
2010
Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Device (RFID), X - Device (Surgical), XX - PA
ClearCount Medical Solutions (Pittsburgh, PA) a commercial-stage company focused on patient safety with RFID tagged surgical smart sponges for surgical reconciliation and operational efficiency, closed a $5M Series B financing. Participants include Draper Triangle Ventures and Draper Fisher Jurvetson.
21
Oct
2010
21
Oct
2010
21
Oct
2010
20
Oct
2010
Posted in I - Series D, Q - 3Q10, R - WEST, X - Oncology, XX - CO
Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.
19
Oct
2010